Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial

Overview of attention for article published in Clinical Cancer Research, May 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

news: 3 news outlets

twitter: 15 X users

Readers on

mendeley: 53 Mendeley

So far, Altmetric has seen 3 news stories from 3 outlets.

Immun- plus Radiochemotherapie beim NSCLC; Krebstote: Hälfte mit Risikofaktor

Medscape, 06 Sep 2022

Im Onko-Blog dieser Woche geht es unter anderem um die Immuntherapie nach Chemoradiotherapie eines Lungenkrebses im Stadium III.

MD Anderson research highlights for August 10, 2022

EurekAlert!, 10 Aug 2022

HOUSTON ― The University of Texas MD Anderson Cancer Centers Research Highlights provides a glimpse into recent basic…

MD Anderson Research Highlights for August 10, 2022

Newswise, 10 Aug 2022

Newswise — HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.